Related Experiment Video
Updated: May 7, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
The new oral anticoagulants in atrial fibrillation: an update
1Heartcenter, Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG), Oosterpark 9, 1091 AC, Amsterdam, the Netherlands, f.w.a.verheugt@olvg.nl.
Abstract:
In patients with nonvalvular atrial fibrillation, oral anticoagulation with the vitamin K antagonists acenocoumarol, phenprocoumon and warfarin reduces the risk of stroke by more than 60 %, whereas single or double antiplatelet therapy is much less effective and sometimes associated with a similar bleeding risk as vitamin K antagonists. Besides bleeding, and intracranial haemorrhage in particular, INR monitoring remains the largest drawback of vitamin K antagonists. In the last decade oral agents have been developed that directly block the activity of thrombin (factor IIa), as well as drugs that directly inhibit activated factor X (Xa), which is the first compound in the final common pathway to the activation of thrombin. These agents have been approved for stroke prevention in atrial fibrillation and are now reimbursed under a national guideline for their safe use. They have advantages in that they do not need monitoring and have a fast onset and offset of action, but lack an established specific antidote. This survey addresses the role of modern anticoagulation for stroke prevention in atrial fibrillation.
Insights
Vitamin K antagonists reduce stroke risk in atrial fibrillation but require monitoring. Newer anticoagulants offer effective stroke prevention without monitoring, improving patient management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Nonvalvular atrial fibrillation increases stroke risk.
- Vitamin K antagonists (VKAs) reduce stroke risk but require INR monitoring and have bleeding risks.
- Antiplatelet therapy is less effective and carries similar bleeding risks as VKAs.
Purpose of the Study:
- To review the role of modern anticoagulation in stroke prevention for nonvalvular atrial fibrillation.
- To compare the efficacy and safety of VKAs with newer oral anticoagulants.
- To discuss the advantages and disadvantages of novel anticoagulant agents.
Main Methods:
- Literature review and survey of current anticoagulation strategies.
- Analysis of clinical trial data on stroke prevention in atrial fibrillation.
- Discussion of pharmacodynamics and clinical application of anticoagulants.
Main Results:
- VKAs reduce stroke risk by over 60% but necessitate INR monitoring.
- Direct oral anticoagulants (DOACs) targeting thrombin (Factor IIa) or Factor Xa offer effective stroke prevention.
- DOACs do not require routine monitoring and have a rapid onset/offset of action.
Conclusions:
- Modern anticoagulants, including DOACs, are valuable for stroke prevention in atrial fibrillation.
- DOACs present advantages over VKAs due to the absence of monitoring requirements.
- Further research is needed regarding specific antidotes for DOACs.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications